Bulk Inquiry
XL 019
- Optical Purity: Optically pure
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C25H28N6O2
- MW: 444.53
Description
More Information
| Parent CAS No. | 945755-56-6 |
|---|---|
| Chemical Name | (S)-N-(4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)pyrrolidine-2-carboxamide |
| SMILES | N1CCC[C@H]1C(NC1=CC=C(C2C=CN=C(NC3=CC=C(N4CCOCC4)C=C3)N=2)C=C1)=O |&1:4,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C25H28N6O2/c32-24(23-2-1-12-26-23)28-19-5-3-18(4-6-19)22-11-13-27-25(30-22)29-20-7-9-21(10-8-20)31-14-16-33-17-15-31/h3-11,13,23,26H,1-2,12,14-17H2,(H,28,32)(H,27,29,30)/t23-/m0/s1 |
| InChiKey | ISOCDPQFIXDIMS-QHCPKHFHSA-N |
| CID | 57990869 |
| Short Description | JAK2 Inhibitor |
References
- S. Verstovsek et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk. Res. 2014, 38, 316-322.
- T. Forsyth et al. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 7653-7658.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1338 | CP 690550 |
From $66.00 |
| 1378 | AG 490 |
From $71.50 |
| 1588 | TG 101348 |
From $88.00 |
| 1598 | Ruxolitinib |
From $71.50 |
| 1681 | Momelotinib |
From $88.00 |
| 1778 | AZ 960 |
From $104.50 |
| 1843 | JAK2 inhibitor 13 |
From $121.00 |
| 1955 | Baricitinib |
From $77.00 |
| 1992 | AS 1517499 |
From $143.00 |
| 2072 | Tofacitinib citrate |
From $126.50 |
| 2217 | PF 956980 |
From $99.00 |
| 2219 | AT 9283 |
From $99.00 |
| 2313 | S3I 201 |
From $99.00 |
| 2314 | Stattic |
From $55.00 |
| 2316 | WP 1066 |
From $104.50 |
| 2517 | Napabucasin |
From $115.50 |
| 2539 | Solcitinib |
From $99.00 |
| 2554 | LY 2784544 |
From $104.50 |
| 2775 | Cerdulatinib |
From $93.50 |
| 2792 | NVP-BSK805 |
From $137.50 |
| 3671 | CEP-33779 |
From $104.50 |
| 3813 | BMS-911543 |
From Inquiry |
| 3855 | AZD-4205 |
From Inquiry |
| 3950 | Peficitinib |
From $132.00 |
